key: cord-0605169-077l6qx1 authors: Tang, Jiabin; Patel, Shivani; Gentleman, Steve; Matthews, Paul title: Neurological Consequences of COVID-19 Infection date: 2021-06-09 journal: nan DOI: nan sha: 73bd6d511d867c113a89e272653cd67374cf98f4 doc_id: 605169 cord_uid: 077l6qx1 COVID-19 infections have well described systemic manifestations, especially respiratory problems. There are currently no specific treatments or vaccines against the current strain. With higher case numbers, a range of neurological symptoms are becoming apparent. The mechanisms responsible for these are not well defined, other than those related to hypoxia and microthrombi. We speculate that sustained systemic immune activation seen with SARS-CoV-2 may also cause secondary autoimmune activation in the CNS. Patients with chronic neurological diseases may be at higher risk because of chronic secondary respiratory disease and potentially poor nutritional status. Here, we review the impact of COVID-19 on people with chronic neurological diseases and potential mechanisms. We believe special attention to protecting people with neurodegenerative disease is warranted. We are concerned about a possible delayed pandemic in the form of an increased burden of neurodegenerative disease after acceleration of pathology by systemic COVID-19 infections. Replication and survival of the virus, is dependent on its ability to bind and 'hijack' host cell machinery, and mimics the behaviour of SARS-CoV and MERS-CoV. 15 SARS-CoV-2 enters cells by binding to angiotensin converting enzyme 2 (ACE2) receptor, which is highly expressed in the epithelial cells of respiratory and gastrointestinal tract, as well as heart, kidney and bladder. [16] [17] [18] Infection is initiated when the envelope spike glycoprotein on the SARS-CoV-2 plasma membrane binds to host cellular receptors, ACE2, which leads to fusion of membranes and entry of the virion into the host cell via endocytosis. The viral RNA genome is then released into the cytoplasm, enabling replication of the viral genome and synthesis of glycoproteins and nucleocapsid proteins for the envelope. The latter components are packaged into virion-containing vesicles, which are released subsequently into the extracellular environment via exocytosis, enabling infection propagation in the host (Figure 1 ). 19 Figure 1 . Potential underlying mechanisms of SARS-CoV-2 'hijacking' host cell machinery. SARS-CoV-2 binds to ACE2 receptor and enters the cell via endocytosis. Then, the viral RNAs are released to cytoplasm, undergoing replication and promoting glycoprotein synthesis. Finally, the new SARS-CoV-2 virus will be released to the extracellular environment by exocytosis. ACE2, angiotensin converting enzyme 2. Due to misdirected host immune responses, respiratory viruses can harm the CNS via autoimmunity. 20 Human CoVs have a similar molecular structure and mode of replication as animal CoVs, such as porcine hemagglutinating encephalitis virus (PHEV), feline coronavirus (FCoV), and mouse hepatitis virus (MHV). [21] [22] [23] CoVs thus are well recognized as being able to invade the CNS and cause viral encephalitis, infectious toxic encephalopathy or acute cerebrovascular disease. 24 25 A CoV-induced encephalomyelitis mouse model was established several years ago, indicating that CoV is able to cause progressive demyelinating neurodegenerative disease. 26 Another study with mouse models has also shown persistence of HCoV-OC43 RNA even one year post-infection in the CNS after intracerebral inoculation. The mice had abnormal reflexes and reduced activity in an open field test, as well as atrophy and neuronal loss in the hippocampus. 27 HCoV-229E and HCoV-OC43, [28] [29] [30] as well as SARS-CoV 31 32 are all neuroinvasive and neurotropic in humans. This has been confirmed by the presence of coronaviral RNA in the human brain, demonstrating that these respiratory pathogens contribute to neurovirulence. 30 33 On 4th March, 2020, gene sequencing confirmed the presence of SARS-CoV-2 in the cerebrospinal fluid (CSF) of a 56-year-old patient in Beijing Ditan Hospital. The patient was diagnosed with viral encephalitis, suggesting that SARS-CoV-2 could potentially invade the CNS, rather than just acting secondary to a systemic immune response. 34 This was the first piece of evidence for direct nervous system invasion by SARS-CoV-2. Subsequently, SARS-CoV-2 has also been observed in neural and capillary endothelial cells in frontal lobe tissue at post-mortem examination. 35 Neurological impairments resulting from SARS-CoV-2 infection include anosmia, ageusia, encephalopathy, prominent agitation, confusion and corticospinal tract signs, as reported in a study where 84% (49/58) of patients experienced these abnormalities. 36 37 Severe infection has also resulted in stroke in some patients. 38 39 Evidence is building that SARS-CoV-2 can enter the brain through (1) hematogenous dissemination -secondary inflammatory activation or ischemia secondary to a systemic coagulopathy, (2) neuronal retrograde disseminationneuronal infection in the periphery and subsequent use of neural transport machinery ( Figure 2 ). 2 40 Potential routes of hematogenous dissemination of SARS-CoV-2 may start with virus entry into the human airways and trans-epithelial entry of the virus into the bloodstream. Monocytes can become activated as a direct virus response and release factors such as MMP9 to increase blood brain barrier (BBB) permeability, as well as pro-inflammatory factors such as TNF-α to upregulate ICAM-1 expression on endothelial cells. This eases the passage of infected and activated monocytes into the CNS, 41 and SARS-CoV-2 is then able to pass through the loosened BBB. 6 Infiltrated infected monocytes activate microglia that produce chemokines (CCL5, CXCL10, CXCL11) and induce chemoattraction of activated T cells or other monocytes. In the meantime, astrocytes may produce other chemokines (CCL2, CCL5 and CXCL12) to aid the recruitment of more infected leukocytes, ultimately initiating a neuroinflammatory loop to cause immune-mediated neuropathology and a systemic inflammatory storm. 11 Hence, systemic inflammation with prolonged hypoxia induces persistent and uncontrolled neuroinflammation, which may underlie clinical manifestations present in patients recovering from pneumonia, including cognitive impairment, behavioural changes and delirium due to cortical deficits, 6 as well as deficits in attention and memory due to hippocampal damage. 6 42 For the neuronal retrograde dissemination method, nasal entry allows viral migration through the neuroepithelium of the olfactory mucosa to the mitral cells, and olfactory bulb thereafter. 44 Subsequently, SARS-CoV-2 may disseminate to the hippocampus and other brain regions via olfactory nerves 11 45 or via synaptic transmission. 46 SARS-CoV-2 is also likely to affect the brainstem heavily 47 48 in a similar manner to SARS-CoV and MERS-CoV, 49 since neural and glial ACE2 expression is prevalent in the brainstem, especially in areas that regulate cardiovascular function. 50 51 Many studies have claimed that the SARS-CoVs seems to have neurotoxicity effects with the interaction of ACE2 in the medullary brainstem, 52 and could induce neurodegeneration, neuroinflammation and astrogliosis. 53 54 The presence of anosmia and ageusia in SARS-CoV-2 infected subjects may also support the hypothesis of nasal route entry of the virus. 37 55 However, Bostanciklioğlu M. argued against it, claiming the glial-lymphatic pathway containing olfactory lymphatic vessels as a direct entry route for SARS-CoV-2 to the brain, which is intriguing and worthwhile for further investigation. 56 Some scientists are aiming to inhibit ACE2 interaction to treat COVID-19, and ACE2-transgenic mice as well as non-human primates are being developed. 57 However, studies have shown that lung injury can be worsened upon decreased ACE2 expression levels, 58 and the overexpression of ACE2 in neuron cells could protect the brain from ischemic stroke, 59 60 so ACE2 inhibitors should be used with caution. A recently published study using human recombinant soluble ACE2 turned out to inhibit SARS-CoV-2 infection successfully in both human blood vessel organoids and human kidney organoids, 61 which could be a promising therapeutic direction. Greater number of co-morbidities and the increased neurodegenerative prevalence with age may mean that patients with neurodegenerative diseases are at greater risk of COVID-19. Patients with advanced Parkinson's Disease (PD) could be particularly vulnerable to SARS-CoV-2, due to rigidity of respiratory muscles, impairment of cough reflex and pre-existing dyspnea. 62 Optimal neurological care has also been compromised due to the pandemic and strain on health care systems. 63 Previously, antibodies against CoVs have been detected in the CSF of PD patients, 64 suggesting that virions could penetrate the blood brain barrier and potentially contribute to the progression of PD. 62 Dopaminergic neurons abundantly express ACE2 on their membranes. Hence, infiltration of SARS-CoV-2 may exacerbate PD-related symptoms. In addition, with more than 50 million people having dementia, a risk of double hit of dementia and COVID-19 could further exacerbate the quality of life for patients. 65 Currently, there is limited data of COVID-19 patients with dementia, but these patients have been reported to be at increased risk for COVID-19 compared to patients without dementia. 66 There are two possible mechanisms that could initiate potential AD development after SARS-CoV-2 infection. Firstly, viral infection into CNS could directly cause neuroinflammation, and theoretically induce microglia and astrocyte activation, as well as disruption of proteostasis (amyloid production and tau phosphorylation). 67 68 Secondly, infiltration of various peripheral cytokines (IL-10, IL-1β, IFN-γ, TNF-α) into the CNS after SARS-CoV-2 incubation also may lead to neuroinflammation and even encephalitis ( Figure 3 ). [69] [70] [71] Numerous viruses have been reported to be closely related to the risk of AD within cohort studies, including herpes simplex virus type 1 (HSV1), human herpesvirus 6 (HHV6) and hepatitis C virus (HCV), although there is still evidence disputing this. 68 72 73 According to incomplete retrospective statistics, 5% to 6% severe COVID-19 patients have been described to have cerebrovascular complications, 27% with brain insults, and 36% -91% with neurologic disorders. 38 74-76 Besides, discoveries have also shown probable relationship between AD genes and increased COVID-19 mortality, and secondary effects of other organ system failure or side-effects of sedatives could also put the patients at exacerbated risk for AD. 77 78 During the SARS and MERS pandemics, evidence has shown the neurotropism of CoV, 53 54 79 and the viral infection has been reported to contribute to the pathophysiology of brain disorders like encephalopathy, dementia, neuropathy and psychosis. 80 81 Because of the nature of chronic diseases, the symptoms may appear years after patients have recovered from viral infection, which makes it easy to overlook the connection. Patients with diabetes, which is one of the major comorbidities for COVID-19, appear to predispose to AD as well according to genetic etiologies. 82 In COVID-19 patients, various CNS symptoms have already been reported, such as headache, consciousness alteration and epilepsy, while brain imaging also showed ischemic infarct, hemorrhage and acute encephalopathy. 83 84 Moreover, the rate of CNS disorders is concordant with the respiratory problem status. 38 Interestingly, memantine, a common drug for AD, appears to have antiviral potential against SARS-CoV-2, 85 indicating the connection of underlying mechanisms between COVID-19 and AD. Memantine, an N-Methyl-D-aspartic acid (NMDA) receptor inhibitor, appears to be a good option for clinical studies, since it could inhibit glutamate release, which is a putative neurotoxic effect of depleted ACE2 (Figure 4 ). 85 86 Memantine has already been reported to be effective against CoV in 2004. 87 In addition, corticosteroid administration has shown progressive clinical improvement in a SARS-CoV-2 infected encephalitis patient, suggesting another possible therapeutic direction. 88 In normal condition, ACE2 is supposed to function as an inhibitor for glutamate release, preventing glutamate over-release in healthy people. (B) SARS-CoV-2 could bind to ACE2 receptor and inhibit ACE2 function, leading to glutamate over-release. Glutamate will then interact with NMDA receptor and cause neurotoxicity. (C) Memantine could bind to NMDA receptors, acting as an antagonist to glutamate. NMDA, N-Methyl-D-aspartic acid. ACE2, angiotensin converting enzyme 2. The SARS-CoV-2 infection could disrupt the brain homeostasis, making the CNS more vulnerable for AD progression even if asymptomatic for decades. Apart from this, interrupted medication of current AD patients could augment neurorehabilitation needs as well. Nevertheless, in a transgenic mouse model, apolipoprotein D, typically overexpressed in PD and AD patients, showed resistance effects against CoV-induced neurodegeneration, which makes us think whether the neurological disorders could protect the individual against CoV in a certain degree. 89 90 The COVID-19 pandemic has been unprecedented in the modern age because of its high infection rate, extent and range of morbidities and, in those more vulnerable, mortality. The need for rapid, more efficient conducted research has led to new way of working through national and international collaborative mechanistic studies and efforts to develop therapies for management and effective vaccines. Increasing the speed of disseminating research data has been fundamental to this. Clinicians, as well as scientists, should be aware and participate in the development of platforms such as the UK National Institute for Health Research National Bioresource, which shares and deploys the data worldwide for neurological disorders associated with COVID-19. 91 Healthcare systems have been forced to modify medical care priorities due to the COVID-19 pandemic in ways that have had a dramatic impact on patients with chronic neurodegenerative conditions. 92 Telemedicine has become a preferred option to deliver urgent and ongoing healthcare. 93 94 However, mental wellbeing for patients with neurodegenerative disease is at risk from the effect of selfisolation and social distancing themselves. 94 95 Physical wellbeing and resilience may be impacted negatively by reductions in physical activity and social interactions; mere lacking regular walking and social interactions, as well as access to physiotherapists or fitness classes has consequences. 96 In addition, many patients and caregivers have not been willing to go to hospital since the onset of pandemic, because of the fear of in-hospital infection; data showed an approximately 50% reduction of 'non-essential' brain disease admissions. 97 98 The normal aging process could also be exacerbated by SARS-CoV-2 infection, in turn leading to higher risk of PD or AD. 99 New approaches for patient management that can accommodate changing clinical practices need to be accelerated. Emerging software tools directed to both neurologists and patients that support the management of chronic diseases and contribute to better mental health are amongst these. 74 100 To date, there is no specific antiviral treatment approved for COVID-19 and no vaccination is currently available. Most hospitals are still relying on symptomatic treatment according to the doctors ' experience, or treatment for comorbidities. Some nonspecific therapies have been proposed based on past experience with SARS and MERS. Clinical tests have been initiated to study the potential of existing antiviral agents, 101 102 interferons, 102 103 immunotherapies, 104 as well as some Chinese medicines. 105 106 Inhibitors of viral RNA polymerase include remdesivir and favipiravir, as well as inhibitors of viral protein synthesis and maturation include lopinavir and ritonavir. 107 108 Promising emerging medicines include a CRISPR-Cas13-based strategy -prophylactic antiviral CRISPR in human cells (PAC-MAN) -has been reported to degrade RNA from SARS-CoV-2 and inhibit viral replication. 109 It is significant to discover if the neurological symptoms are caused by viral entry or secondary immune response, since the treatment scenarios could be completely different. 110 Multiple vaccines are being developed, including mRNA-1273, Ad5-nCoV, INO-4800, LV-SMENP-DC and pathogen-specific artificial antigen-presenting cell (aAPC). 111 A general concern with these efforts is the extent, rate and impact of CoV mutations (e.g. of surface spike proteins) likely to occur over time after prolonged CNS infection and thus the efficacy and durability of potential protection. 87 Several mutations have been reported recently for SARS-CoV-2 in Non-Structural Protein 6 (NSP6), Open Reading Frame 10 (ORF10) adjacent region and S1 domain, 112 113 as well as changed binding capacity with ACE2. 114 One specific vaccine is unlikely to be enough, even if it is highly effective in a segment of the population. All vaccines also carry the potential for adverse effects, which means we have to be cautious in multiple ways. To sum up, attention should be focused on the relationship between COVID-19 and neurodegenerative diseases for two main reasons: (1) SARS-CoV-2 infection may cause neuroinflammation which, in turn, may hasten the progression of some neurodegenerative disorders; (2) as neurodegenerative patients cannot take care of themselves, the quarantine itself may have negative consequences for the cognition and function, potentially contributing to their vulnerability to SARS-CoV-2 infection with exposure. Although the long-term consequences of SARS-CoV-2 infection in the brain are unclear, there is enough evidence in the literature to suggest that infection may exacerbate some CNS disorders. Resistance and resilience to any viral infection relies on a balanced immune response, which can be dysfunctional with aging and neurological diseases or their antecedents. 115 Given the prominence of respiratory symptoms, there is a risk for doctors to overlook consequences for the brain pathology. As we anticipate recurrent flare of infection, neurological care -more than ever -needs to be delivered using multi-disciplinary teams including neurorehabilitation, nutritional and social care professionals. 115 116 Characterising and understanding long-term outcomes of SARS-CoV-2 infections and other deleterious impacts now is a priority to be pursued through partnerships between academia and the NHS. Coronavirus infections-more than just the common cold Novel coronavirus and the central nervous system COVID-19: what has been learned and to be learned about the novel coronavirus disease Cross -species transmission of the newly identified coronavirus 2019-nCoV The COVID-19 epidemic Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19 People of Any Age with Underlying Medical Conditions Centres for Disease Control and Prevention2020 La encefalitis letárgica de von Economo y la pandemia de la gripe española en Bogotá y Medellín: reseña histórica cien años después Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection The novel coronavirus originating in Wuhan, China: challenges for global health governance Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis MERS: emergence of a novel human coronavirus Host factors in coronavirus replication. Roles of Host Gene and Non-coding RNA Expression in Virus Infection Interspecies transmission and emergence of novel viruses: lessons from bats and birds Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Mechanism of demyelination in JHM virus encephalomyelitis A hemagglutinating virus producing encephalomyelitis in baby pigs Inflammation and changes in cytokine levels in neurological feline infectious peritonitis Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland Nervous system involvement after infection with COVID-19 and other coronaviruses Alterations in nerve-evoked bladder contractions in a coronavirus-induced mouse model of multiple sclerosis Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice Acute and persistent infection of human neural cell lines by human coronavirus OC43 Infection of primary cultures of human neural cells by human coronaviruses 229E and OC43 Neuroinvasion by human respiratory coronaviruses Multiple organ infection and the pathogenesis of SARS Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis Inflammation in neuroviral diseases Sars-Cov-2: Underestimated damage to nervous system Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS -CoV -2) Neurologic features in severe SARS-CoV-2 infection Anosmia and ageusia: common findings in COVID-19 patients Neurologic manifestations of hospitalized patients with coronavirus disease Neurologic complications of coronavirus infections Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms Activation of human monocytes after infection by human coronavirus 229E Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms Epithelium & lamina Propria) An Online Examination of Human Anatomy and Physiology: Get Body Smart SARS-CoV-2: a new virus but a familiar inflammation brain pattern HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2 Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4 Angiotensin-converting enzyme 2: central regulator for cardiovascular function Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment COVID-19: ICU delirium management during SARS-CoV-2 pandemic Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS -CoV) in SARS patients: implications for pathogenesis and virus transmission pathways Loss of sense of smell as marker of COVID-19 infection SARS-CoV2 entry and spread in the lymphatic drainage system of the brain The COVID-19 vaccine development landscape Angiotensin-converting enzyme 2 protects from severe acute lung failure Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic efficacy COVID-19-Related Stroke Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Outcome of Parkinson's Disease patients affected by COVID-19 Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease Dementia care during COVID-19 COVID -19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US Covid-19 and neurodegeneration. What can we learn from the past? HHV-6A infection dysregulates autophagy/UPR interplay increasing beta amyloid production and tau phosphorylation in astrocytoma cells as well as in primary neurons, possible molecular mechanisms linking viral infection to Alzheimer's disease Letter to editor: Severe brain haemorrhage and concomitant COVID-19 Infection: A neurovascular complication of COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer's disease Human herpesvirus 6 detection in Alzheimer's disease cases and controls across multiple cohorts Hepatitis C viral infection and the risk of dementia Endovascular Therapy for Patients With Acute Ischemic Stroke During the COVID-19 Pandemic: A Proposed Algorithm New -onset acute symptomatic seizure and risk factors in Corona Virus Disease 2019: A Retrospective Multicenter Study Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection Clinical Features, and Genetic Risk Factors Associated with Symptoms of COVID-19 in a Cohort of Older People in Madrid ApoE-isoform-dependent SARS-CoV-2 neurotropism and cellular response Multiple organ infection and the pathogenesis of SARS Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies Brain MRI Findings in Patients in the Intensive Care Unit with COVID-19 Infection Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study The Potential of Memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects Evidence for Lysosomotropism of Memantine in Cultured Human Cells: Cellular Kinetics and Effects of Memantine on Phospholipid Content and Composition, Membrane Fluidity and β -Adrenergic Transmission Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus Steroid -responsive encephalitis in Covid-19 disease Binding and repressive activities of apolipoprotein E3 and E4 isoforms on the human ApoD promoter Neuroprotective effect of apolipoprotein D against human coronavirus OC43-induced encephalitis in mice Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. The Lancet Psychiatry The invisible hand-medical care during the pandemic The promise of telemedicine for movement disorders: an interdisciplinary approach Management of Advanced Therapies in Parkinson's Disease Patients in times of Humanitarian crisis: the COVID -19 experience Parkinson's disease and COVID-19: Perceptions and implications in patients and caregivers The impact of the COVID-19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities Challenges and potential solutions of stroke care during the coronavirus disease 2019 (COVID-19) outbreak: Am Heart Assoc Disability through COVID -19 pandemic: Neurorehabilitation cannot wait SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes Guidelines for TMS/tES Clinical Services and Research through the COVID-19 Pandemic Approved antiviral drugs over the past 50 years Therapeutic options for the 2019 novel coronavirus (2019-nCoV) CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment CSC2020 Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infectious Diseases Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza How COVID-19 can damage the brain The COVID-19 vaccine development landscape Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Using psychoneuroimmunity against COVID-19 Handbook of COVID-19 prevention and treatment PMM acknowledges generous personal and research support from the Edmond J Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. This work also is supported by the UK Dementia Research Institute, which received its funding from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. Infrastructure was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC). We also acknowledge the support from Getbodysmart website for a kind permission to reproduce their figure. Authors' contributions: JT and SP wrote the primary draft. JT drawed all the figures, except for the one from Getbodysmart website. PMM and SG revised and edited the primary draft. All authors read and approved the final manuscript.